Guidelines for primary aldosteronism: uptake by primary care physicians in Europe by Mulatero, Paolo et al.
Guidelines for Primary Aldosteronism: Uptake by Primary Care Physicians in Europe. 1 
Paolo Mulatero1*, Silvia Monticone1*, Jacopo Burrello1, Franco Veglio1, Tracy A. Williams1, John 2 
Funder2. 3 
*These authors contributed equally to the study 4 
Affiliations: 5 
1- Division of Internal Medicine and Hypertension, Department of Medical Sciences, University of 6 
Torino, 10126 Torino, Italy  7 
2- Department of Steroid Biology, Hudson Institute of Medical Research and Monash University, 8 
Clayton, Victoria 3168, Australia. 9 
Short title: general practitioners and endocrine guidelines 10 
Keywords: primary aldosteronism, endocrine hypertension, aldosterone, general practitioners 11 
Corresponding authors: Paolo Mulatero, Division of Internal Medicine and Hypertension, 12 
Department of Medical Sciences, University of Torino, Via Genova 3, 10126, Torino, Italy.  13 
e-mail: paolo.mulatero@unito.it; fax: +39-0116336931; ph: +39-0116336959 14 
and John W. Funder, Department of Steroid Biology, Hudson Institute of Medical Research and 15 
Monash University, Clayton 27-31 Wright Street, Clayton, Victoria 3168, Australia.  16 
e-mail: john.funder@hudson.org.au 17 
Authors disclosure/conflict of interest: the authors have nothing to disclose 18 
Source of funding: the study was partially supported by an unrestricted grant from DIASORIN to 19 
the Department of Medical Sciences, University of Torino, Italy. 20 
Word count: abstract: 232; manuscript: 2781 (excluded references and figure captures); 2 figures; 21 
1 supplemental file.22 
 2 
Abstract  23 
Context: Primary aldosteronism (PA) is the most frequent form of secondary hypertension 24 
but is still markedly underdiagnosed. In 2008 the Endocrine Society released guidelines for 25 
PA diagnosis and management; current indications are that they are not being widely 26 
followed. Objective: To investigate the level of knowledge and application of the guidelines 27 
in a large representative cohort of general practitioners (GPs) in Italy and Germany. Setting 28 
and Design: The study was carried out by web questionnaire on hypertension and PA 29 
management with 500 GPs (250 in Italy and 250 in Germany), stratified by geographical 30 
area and city size. Results: The mean number of patients seen was 1747 (Germany) and 31 
1388 (Italy). Of these, 18% were diagnosed as hypertensive in Italy and 25% in Germany. 32 
Renin and aldosterone measurements were ordered by 7% of GPs in Italy and 8% in 33 
Germany. GPs in Italy considered 8% of patients eligible for aldosterone and renin 34 
measurements compared to 13% of GPs in Germany. In Italy, PA prevalence was 1% 35 
among hypertensive patients; 36% of the GPs reported no PA patients under their care or 36 
diagnosed previously. In Germany, the prevalence of PA was 2% among hypertensive 37 
patients; 19% of GPs had no PA patients. Conclusions: in Germany and in Italy, PA is not 38 
widely recognized by GPs; Endocrine Society guidelines for PA diagnosis are not well known 39 
or applied, resulting in marked underdiagnosis of the disease. 40 
 41 
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Introduction 48 
In 2008 the Endocrine Society published guidelines for the case detection, diagnosis and 49 
treatment of primary aldosteronism (1), co-sponsored by the European Society of 50 
Endocrinology. These guidelines recommended screening for primary aldosteronism in the 51 
~30% of patients with a substantial risk of PA. Hypertension per se is a major driver of 52 
cardiovascular morbidity and mortality; the diagnosis of PA is of particular importance given 53 
the markedly higher risk profile than that in age-, sex-, and blood pressure-matched 54 
essential hypertension (2,3). The guidelines published by the Japan Endocrine Society in 55 
2011 recommend screening all hypertensive patients for PA (4); in the revised guidelines 56 
recently published by the Endocrine Society in 2016 (5) the previous recommendation has 57 
been expanded to ~50% of hypertensives. 58 
While such recommendations can be justified in theory, it is difficult to see how in the 59 
foreseeable future they might be put into practice. In developed countries it is estimated that 60 
20-40% of the adult population have high blood pressure (BP). The estimated prevalence of 61 
PA currently varies from ~5% of hypertensives to >10%, a range reflecting strict or more 62 
relaxed cut-offs for plasma aldosterone concentration (PAC), plasma renin 63 
activity/concentration (PRA/PRC) and the aldosterone to renin ratio (ARR). If we take a 64 
figure of 30% for the prevalence of adult hypertension, this gives us ~ 70 million 65 
hypertensives in the USA, ~30 million in Japan, and ~15 million in Italy. Merely to tread 66 
water would require 4 million hypertensives to be screened each year in the US, 2 million in 67 
Japan and 1 million in Italy. 68 
There is a general consensus that screening rates are in fact very much lower, and the 2016 69 
guidelines are accompanied by a desk regerence module for primary care physicians in an 70 
attempt to increase screening of patients at high risk of PA. The present study was 71 
undertaken to establish the extent to which primary care physicians (also known as general 72 
practitioners) are aware of the guidelines, and secondly their familiarity with the 73 
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management of primary aldosteronism. The study took place in Italy and Germany; in both 74 
these countries there are outstanding academic and clinical contributors to the fields of PA. 75 
There is much in common between the two countries’ responses, and some differences. 76 
What it shows, in brief, is a yawning gap between theory, as laid down in guidelines, and 77 
practice. It is likely that a similar gap exists throughout the world. 78 
 79 
Materials and Methods 80 
The study was directed by the Department of Medical Sciences at the University of Turin, 81 
approved by the University’s Institutional Review Board and supported by an untied grant 82 
from Diasorin s.p.a. The questionnaire was posed to 250 physicians in Italy and 250 in 83 
Germany by the market research firm Stethos srl using the CAWI (Computer Assisted Web 84 
Interviewing) methodology. All web interviews were collected between November 2013 and 85 
January 2014. The physicians chosen cared for at least one thousand monitored patients, 86 
and were stratified on the basis of practice location (village/small town/large town etc.) and 87 
geographical area (e.g. North, Centre, South of Italy, plus East and West for Germany). The 88 
questionnaire is complex, and physicians were recompensed for lost practice time. Data 89 
analysis was done by Stethos, specialists in market research in the field of healthcare 90 
(Stethos, Milan, Italy) in combination with University personnel. All of the physicians who 91 
took part gave their written consent, and a copy of the questionnaire is included in the 92 
supplementary materials on-line. 93 
 94 
Results 95 
A cross sectional comparison of the two countries' responses is shown in Table 1.  96 
As might be expected, there are both commonalities and differences between the two 97 
groups of physicians. Among the commonalities are near-identical systolic (SBP) and 98 
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diastolic (DBP) levels of blood pressure; the presenting symptoms (headache/dizziness 99 
together comprise 80% in both countries); a female (57-59%) to male (42-43%) 100 
preponderance in both groups; an identical figure for the diagnostician of resistant 101 
hypertension (specialists 54%, primary care physicians 46%); and finally an identical figure 102 
for the percentage (8%) of patients diagnosed with resistant hypertension. 103 
Some differences between the two groups may be relevant for the diagnosis of PA, others 104 
may not. On average, German physicians were responsible for 1747 patients, their Italian 105 
counterparts for 1388. The Italians diagnosed hypertension in 18% of their patients, the 106 
Germans 25%. Both groups referred patients primarily to cardiologists (Italy 74%, Germany 107 
59%) with lesser percentages to Departments of Medicine and specialized Hypertension 108 
Centres. The Italians were apparently much more in favour of monitoring renin and 109 
aldosterone (rating its importance on a scale from 1 to 10, 6.4/10 vs 5.4/10 in Italy and 110 
Germany, respectively), but despite this, sent only on average just over half as many 111 
(5/4/11) each year for PAC/renin/ARR measurements as their German counterparts (8/8/15). 112 
Of the Italian respondents, 36% had no patients with PA, almost double the figure for 113 
Germany (19%). On average 1% of all the Italian hypertensives were diagnosed with PA, 114 
and 2% of German (Figure 1).  115 
At diagnosis of hypertension 50% of GPs in Italy and 43% of GPs in Germany ordered 116 
diagnostic tests. Plasma potassium levels were only requested by 43% (Italy) and 58% 117 
(Germany); renin and aldosterone measurements by 7% (Italy) and 8%(Germany) (Figure 118 
2); of note renin and aldosterone levels were measured in only 3% of patients before starting 119 
pharmacological therapy in both countries. No GP’s recognized hyperaldosteronism as a 120 
cause of resistant hypertension, or ordered renin and aldosterone measurements before 121 
changing any therapy.  122 
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Notwithstanding the numbers of tests actually requested, 8% of patients were considered 123 
potentially eligible for aldosterone and renin measurement by GPs in Italy compared to 13% 124 
of patients  by GPs in Germany.  125 
In short, there is widespread acceptance of the existence of resistant hypertension in both 126 
countries, although the common figure (8%) is low, even with false diagnosis due to 127 
compliance failure factored in. Almost half the physicians in both groups are confident to 128 
diagnose and manage resistant hypertension: there is no mention of mineralocorticoid 129 
receptor antagonists (MRAs) among the list of current therapies, and ‘other’ is a figure well 130 
below 8%. In contrast, recognition of PA seems to vary widely: whereas in Germany 19% of 131 
physicians have no PA patients, 11% have >20 and another 20% 10-20 such patients, for 132 
example. These latter practitioners thus have a prevalence for PA more or less in the normal 133 
range for strict cut-offs, or ~5% of hypertensives. However, the figures are overall not 134 
reflective of current best practice - ~1% of all hypertensives in Italy, and ~2% in Germany. 135 
 136 
Discussion 137 
The findings of the survey will be discussed under three headings. The first is a 138 
consideration of the results found from the survey. The second is an attempt to address the 139 
basis of the physicians’ responses, their causes and what these causes might imply. The 140 
third is to suggest how the situation might be improved, as simply and as economically as 141 
possible. 142 
In terms of study itself, there are a number of inevitable limitations. The data were generated 143 
by web interview. The questions are often simple, but often also requiring numeric answers: 144 
responses by web are thus likely to be ‘ball-park’ figures. Secondly, in both countries over 145 
80% of patients presented with headache and /or dizziness, unremarkable given the average 146 
blood pressure at first visit (Italy 167/97, Germany 170/99). What are remarkable are two 147 
issues. First there appear to be no data on incidental finding of raised blood pressure, which 148 
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is common in jurisdictions where blood pressure measurement is a routine part of any but 149 
the most trivial general practice consultation. Secondly, these average values are very high, 150 
and in both countries presumably indicate a substantial number of subjects with even higher 151 
values. Given the documented increase in prevalence of PA progressively with increased 152 
blood pressure (1), the patient cohorts under study are likely to have levels of PA well above 153 
the average for unselected primary care patients (6) of ~5%. This makes the finding of only 154 
1-2% even more disappointing. 155 
There are, in addition a number of differences between the two cohorts that need to be 156 
addressed. The difference in prevalence of hypertension reported (Italy 15%, Germany 157 
25%), taken with the equivalent values for blood pressure at time zero, is not easy to explain 158 
on the basis of genetics, epigenetics or lifestyle: a possible explanation is that there is a 159 
lower rate of consultation in Germany for reasons other than hypertension. While the 160 
percentage referral to a specialist is similar (Italy 15.2%, Germany 17.5%) , in Italy 74% of 161 
referred patients are seen by a cardiologist, while in Germany the percentage is 59%. For 162 
the patients that remain in primary care, in Germany appropriately and unsurprisingly 99.5% 163 
of patients undergo BP monitoring, compared with 78.1% in Italy. In both countries the 164 
percentage of patients who appear to have resistant hypertension is the same (8%), and in 165 
both countries this seems to be the primary focus. In both countries substantial blood 166 
pressure lowering in response to treatment was reported: however calculated, in Germany 167 
this was 20-21%, and – given clearly less aggressive pharmacotherapy – a surprising figure 168 
of 40-42% in Italy. Similarly surprising was that in a substantial minority of patients (Italy 169 
23%, Germany 34%) hypertension was considered secondary to heart disease, rather than 170 
the converse. 171 
In terms of the basis of the physicians’ responses, their causes and what these causes might 172 
imply, there are almost certainly a variety of contributing factors. Many physicians were 173 
taught that primary aldosteronism is a rare (<1%) and relatively benign cause of secondary 174 
hypertension, both of which we now know not to be the case. As previously noted, 36% of 175 
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primary care physicians in Italy, and 19% in Germany, profess to have no case of primary 176 
aldosteronism among their hypertensive patients. The questionnaire details average patient 177 
ages, at presentation and at the time of interview: no data were presumed for physicians’ 178 
age. If physicians’ age data are available, it would also be of interest to look at those who 179 
have >10 and >20 patients with primary aldosteronism under their care. 180 
Secondly, in both countries around half of the respondents knew of the guidelines, but there 181 
were no data on what percentage were actually conversant with their recommendations. 182 
Direct questions on content might have been regarded as too intrusive, but indirect 183 
questions (“At what level of presenting blood pressure is it appropriate to test for primary 184 
aldosteronism?” “What do you regard as the percentage of hypertensives whose condition is 185 
due to primary aldosteronism?”) would have been useful, and added to what can only be 186 
surmised from the number of patients with primary aldosteronism in your practice question. If 187 
possible, a finer-grained analysis of those respondents with >10 or >20 primary aldosterone 188 
patients might also be illuminating – not just age, but practice location, referral patterns and 189 
so on. 190 
Referral patterns – the major speciality relied upon being cardiology – might also underlie 191 
the low discovery rates. In Germany, when patients are referred it is to cardiologists in three 192 
fifths of cases, and in Italy three quarters. In most jurisdictions there are far more 193 
cardiologists than endocrinologists, with the latter largely occupied with diabetes, thyroid 194 
disease and reproductive issues. Although primary aldosteronism is primarily an endocrine 195 
disorder, with secondary cardiovascular and renal consequences, not all endocrinologists 196 
are practised in its management: referral for suspected primary aldosteronism should 197 
therefore be to an endocrinologist familiar with the condition, or to a specialised hypertension 198 
centre with an appropriate track record and personnel. This latter in fact should be the case 199 
for all referred patients: although clearly some cardiologists are skilled in managing 200 
hypertension, it is – as noted previously – a condition in which cardiac effects are secondary, 201 
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and more specialised skills – in vascular biology, clinical pharmacology, neuroscience and 202 
endocrinology – are more suited to identify and rectify the root causes. 203 
A fourth possible reason for under-diagnosis is that of the cost to the patient, immediate and 204 
future. Ordering of tests at presentation is much more common in Italy than in Germany – for 205 
example, the percentage of hypertensives undergoing ECG examination is over 10-fold 206 
higher, and creatine levels over 9-fold higher – so no common attitude to testing appears to 207 
exist. In fact, the costs of doing a aldosterone to renin ratio are not prohibitive, and easily 208 
outweighed by the savings in appropriate management. Probably of less immediate concern 209 
are the costs consequent upon confirmation of primary aldosteronism – exclusion testing, 210 
imaging, lateralization, and surgery in the case of unilateral disease. As will be further 211 
discussed, those are real concerns, but almost certainly a minor contributor to the very low 212 
level of case detection. 213 
Finally, a cause for under diagnosis may be a fear of ‘losing the patient’, particularly if 214 
referral is made to an unfamiliar endocrinologist/ hypertension centre rather than a familiar 215 
cardiologist colleague. There are no direct questions in the survey bearing on this: the 216 
finding that over 25% of German physicians have >10 patients with primary aldosteronism 217 
(10-19 15%, ≥20 11%) compared with Italy (10-19 10%, ≥20 2%) fits with the much higher 218 
referral rate to cardiologists. That such patients remain in the primary care physicians 219 
practice is evidence that not all referred patients are lost; what is not clear is the percentage 220 
that may be. What may or may not be relevant is the u-shaped curve for the number (0, 1, 2, 221 
3, 4, 5-9, 10-19, ≥20) of patients in each practice, with a nadir at 4 in both countries (Italy 222 
4%, Germany 1%), a much lower figure than that for 0/1/2/3. 223 
Given the findings of the survey, broad ranging but inevitably limited, how might the situation 224 
be improved, as simply and as economically as possible? First might be the translation and 225 
distribution of the Endocrine Society’s Guidelines’ accompanying desk reference; the cost is 226 
relatively trivial, and the distribution might be accompanied by an explanatory letter from the 227 
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German and Italian members of the Guidelines taskforce. Secondly, in terms of cost, one of 228 
the key recommendations of the 2016 guidelines needs to be highlighted, which is that if 229 
patients test positive on the case detection step (determining the aldosterone to renin ratio) 230 
but are unwilling or unable to proceed they should have a mineralocorticoid receptor 231 
antagonist included in their antihypertensive therapy. To the extent that either cost to the 232 
patient, or understandable bottlenecks in the optimal patient pathway 233 
(confirmation/imaging/lateralization/unilateral adrenalectomy) make entry into the pathway 234 
difficult, a low dose mineralocorticoid antagonist is an important addition. Recognition of this 235 
course of action for ‘low-grade’ possible PA (moderate hypertension, normokalemic, 236 
modestly elevated ARR, PAC in normal range) may thus encourage primary care physicians 237 
to order more ARR testing in their hypertensive patients - or failing that, a simple renin 238 
determination. (7,8) 239 
The importance of this, what might be termed an interim strategy, is that there is increasing 240 
evidence that ‘inappropriate aldosterone secretion’ – i.e. primary aldosteronism – might 241 
contribute to elevated blood pressure in 30-50% of hypertensive patients, rather than 5-10%. 242 
The first substantial study to suggest this (9) was published over 30 years ago; more 243 
recently, there is clear evidence for mineralocorticoid receptor activation contributing to 244 
blood pressure elevation in resistant hypertension (10), low renin hypertension (11) and 245 
simple uncomplicated essential hypertension (12). In these latter cases, the ligand activating 246 
mineralocorticoid receptors may not be aldosterone, but cortisol in the context of tissue 247 
damage. On the other hand, recent studies from Athens suggest very strongly that the true 248 
prevalence of primary aldosteronism in hypertension may be ~50%, reflecting neglect of 249 
ACTH as a secretagogue (13, 14). 250 
Whatever the prevalence of primary aldosteronism overall, it is likely that that of aldosterone 251 
producing adenomas will remain close to its currently accepted levels, i.e. 3-4% of 252 
hypertensives. Patients with APA commonly have more florid disease (higher PAC, ARR, 253 
blood pressure and incidence of hypokalemia), and are thus more easily ascertained. 254 
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Unfortunately the questionnaire did not address the outcomes of diagnosis of primary 255 
aldosteronism in either country – whether most or all so diagnosed were patients with 256 
aldosterone producing adenoma. 257 
Primary aldosteronism is a rapidly moving field, and the advances of the past couple of 258 
decades are obviously yet to be appreciated and acted upon by the profession. To the effect 259 
that they have been, primary care physicians today may be discouraged in terms of 260 
screening, let alone committing a patient to an agreed pathway of ideal treatment, for 261 
reasons of cost: capacity limitations, particularly of interventionists skilled in adrenal venous 262 
sampling, are an additional stumbling block. Over the next decade (perhaps even the next 263 
five years) appreciation of the role of mineralocorticoid receptor activation – by 264 
inappropriately high aldosterone levels, or by normal levels of cortisol in the context of tissue 265 
damage – may begin to increase the use of inexpensive, low dose minimal side-effect 266 
mineralocorticoid receptor antagonists as part of first line therapy in hypertension. 267 
268 
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Figure Legends 316 
Figure 1. Prevalence of primary aldosteronism, other forms of secondary hypertension and 317 
essential hypertension in Italy and Germany.  318 
Figure 2. Proportion of patients screened for PA or not, and with a final diagnosis of PA, in 319 
Italy and Germany. 320 
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 322 
Questionnaire for GPs Italy Germany 
Number of patients seen by each GP (mean) 1388 1747 
Prevalence of HTN (%) 18 25 
SBP/DBP on diagnosis of HTN (mean, mmHg) 167/97 170/99 
Prevalence of resistant HTN (%) 7.6 7.9 
Patients ordered tests on diagnosis of HTN (%) 50 43 
Plasma [K+] measured on diagnosis of HTN (%) 43 58 
Aldosterone and renin measurement on diagnosis of HTN (%) 7 8 
Aldosterone and renin measurement before drug therapy (%) 3 3 
Awareness of the ES guidelines for PA (%) 53 59 
Patients tested last year for aldosterone alone/renin alone/both 5/4/11 8/8/15 
GPs reporting no patients with PA (%) 36 19 
Overall reported PA prevalence in HTN (%) 1 2 
 323 
Table 1. Relevant questions and replies on PA awareness by Italian and German general 324 
practitioners. 325 
GPs= general practitioners; PA= primary aldosteronism; HTN= hypertension; ES= Endocrine Society.  326 
 327 
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 330 
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